Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KY-0301 Monotherapy in Advanced Solid Tumors
NCT06928363Phase 2Not yet recruiting
- Sponsor
- Novatim Immune Therapeutics
- Start
- May 2025
- Primary completion
- Nov 2027
- Modality
- Antibody-Drug Conjugates (ADCs), Nanobodies (VHH), Small Molecules
01
Overview
Phase 2, open-label trial of KY-0301 in solid tumor, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (5 arms), sponsored by Novatim Immune Therapeutics. Primary endpoints: Occurrence of Dose-Limiting Toxicity at 28 days and Maximum Tolerated Dose up to 24 Months. Planned start May 2025; status: not yet recruiting.
02
Drugs
KY-0301
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06928363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06928363.